上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2024 , Vol. 44 >Issue 1: 64 - 71

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.01.007

论著 · 临床研究

甲状腺弥漫性大B细胞淋巴瘤临床病理特征、基因突变谱及预后分析

  • 杜沚珊 ,
  • 王玥 ,
  • 石子旸 ,
  • 施晴 ,
  • 易红梅 ,
  • 董磊 ,
  • 王黎 ,
  • 程澍 ,
  • 许彭鹏 ,
  • 赵维莅
展开
  • 上海交通大学医学院附属瑞金医院血液科，医学基因组学国家重点实验室，上海血液学研究所，上海 200025
杜沚珊（2000—），女，硕士生；电子信箱：14743888962@163.com。
许彭鹏，电子信箱：pengpeng_xu@126.com.

收稿日期: 2023-06-01

  录用日期: 2023-10-25

  网络出版日期: 2024-01-28

基金资助

国家自然科学基金(82130004);上海交通大学医学院“双百人”项目(20230013)

收起

Clinicopathologic characteristics, gene mutation profile and prognostic analysis of thyroid diffuse large B-cell lymphoma

  • Zhishan DU ,
  • Yue WANG ,
  • Ziyang SHI ,
  • Qing SHI ,
  • Hongmei YI ,
  • Lei DONG ,
  • Li WANG ,
  • Shu CHENG ,
  • Pengpeng XU ,
  • Weili ZHAO
Expand
  • Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai 200025, China
XU Pengpeng, E-mail: pengpeng_xu@126.com.

Received date: 2023-06-01

  Accepted date: 2023-10-25

  Online published: 2024-01-28

Supported by

National Natural Science Foundation of China(82130004);"Two-hundred Talents" Program of Shanghai Jiao Tong University School of Medicine(20230013)

Fold

摘要

目的·探究甲状腺弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）临床病理特征、基因突变谱及预后相关因素。方法·回顾性分析2003年11月—2021年12月上海交通大学医学院附属瑞金医院收治的66例初次诊断为甲状腺DLBCL患者［原发甲状腺DLBCL 23例（34.8%），继发甲状腺DLBCL 43例（65.2%）］的临床病理资料，并进行生存和预后因素分析。其中40例甲状腺DLBCL患者进行了靶向测序（55个淋巴瘤相关基因）以评估基因突变情况。结果·继发甲状腺DLBCL患者Ann Arbor分期Ⅲ~Ⅳ期（P=0.000）、乳酸脱氢酶（lactate dehydrogenase，LDH）升高（P=0.043）、结外器官受累数目≥2个（P=0.000）、非生发中心来源（non-GCB）（P=0.030）、MYC和BCL2蛋白双表达（double expression，DE）（P=0.026）、国际预后指数3~5分（P=0.000）的比例高于原发甲状腺DLBCL患者，其接受甲状腺手术切除的比例（P=0.012）低于原发甲状腺DLBCL患者。原发甲状腺DLBCL患者完全缓解（complete response，CR）率高于继发患者（P=0.039）。55例患者（83%）接受以利妥昔单克隆抗体联合环磷酰胺、阿霉素、长春新碱及泼尼松（R-CHOP）为基础的一线治疗方案，其中原发甲状腺DLBCL患者预期5年无进展生存（progress free survive，PFS）率95.0%，高于继发患者的49.7%（P=0.010）。单因素分析显示：Ann Arbor Ⅲ~Ⅳ期（HR=4.411，95%CI 1.373~14.170）、LDH升高（HR=5.500，95%CI 1.519~19.911）、non-GCB（HR=5.291，95%CI 1.667~16.788）、DE（HR=6.178，95%CI 1.813~21.058）是甲状腺DLBCL患者PFS的不良预后因素；Ann Arbor Ⅲ~Ⅳ期（HR=7.088，95%CI 0.827~60.717）、LDH升高（HR=6.982，95%CI 0.809~60.266）、DE（HR=18.079，95%CI 1.837~177.923）是总生存（overall survival，OS）时间的不良预后因素。多因素分析显示：Ann Arbor Ⅲ~Ⅳ期（HR=4.693，95%CI 1.218~18.081）和LDH升高（HR=5.058，95%CI 1.166~21.941）是甲状腺DLBCL患者PFS的独立不良预后因素。靶向测序结果显示，TET2（n=14，35%）、KMT2D（n=13，32%）、TP53（n=11，28%）、GNA13（n=10，25%）、KMT2C（n=9，22%）突变频率>20%，且TP53突变是甲状腺DLBCL患者PFS的不良预后因素（P=0.000）。结论·原发甲状腺DLBCL生存情况优于继发甲状腺DLBCL。Ann Arbor Ⅲ~Ⅳ期、LDH升高、non-GCB、DE（MYC和BCL2）是影响甲状腺DLBCL患者的不良预后因素。TET2、KMT2D、TP53、GNA13、KMT2C是甲状腺DLBCL中常见的高突变基因，TP53突变的患者预后不佳。

关键词： 甲状腺; 弥漫性大B细胞淋巴瘤; 临床病理特征; 基因突变谱; 预后分析

本文引用格式

杜沚珊 , 王玥 , 石子旸 , 施晴 , 易红梅 , 董磊 , 王黎 , 程澍 , 许彭鹏 , 赵维莅 . 甲状腺弥漫性大B细胞淋巴瘤临床病理特征、基因突变谱及预后分析[J]. 上海交通大学学报（医学版）, 2024 , 44(1) : 64 -71 . DOI: 10.3969/j.issn.1674-8115.2024.01.007

Abstract

Objective ·To analyze the clinicopathologic characteristics, gene mutation profile, and prognostic factors of thyroid diffuse large B-cell lymphoma (DLBCL). Methods ·From November 2003 to December 2021, a total of 66 patients with thyroid DLBCL [23 cases (34.8%) with primary thyroid DLBCL, and 43 cases (65.2%) with secondary thyroid DLBCL] admitted to Ruijin Hospital, Shanghai Jiao Tong University School of Medicine were retrospectively analyzed for their clinicopathological data, survival and prognostic factors. Gene mutation profiles were evaluated by targeted sequencing (55 lymphoma-related genes) in 40 patients. Results ·Compared to primary thyroid DLBCL, secondary thyroid DLBCL had advanced ratio of Ann Arbor stage Ⅲ?Ⅳ (P=0.000), elevated serum lactate dehydrogenase (LDH) (P=0.043), number of affected extranodal involvement ≥2 (P=0.000), non-germinal center B cell (non-GCB) (P=0.030), BCL-2/MYC double expression (DE) (P=0.026), and international prognostic index (IPI) 3?5 -scores (P=0.000). The proportion of patients who underwent thyroid surgery (P=0.012) was lower than that of patients with primary thyroid DLBCL. The complete remission (CR) rate in primary thyroid DLBCL patients was higher than that in secondary thyroid DLBCL patients (P=0.039). Fifty-five patients (83%) received rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based first-line regimen. The estimated 5-year progression free survival (PFS) rate of primary thyroid DLBCL patients was 95.0%, higher than the 49.7% of the secondary patients (P=0.010). Univariate analysis showed that Ann Arbor Ⅲ?Ⅳ (HR=4.411, 95%CI 1.373?14.170), elevated LDH (HR=5.500, 95%CI 1.519?19.911), non-GCB (HR=5.291, 95%CI 1.667?16.788), and DE (HR=6.178, 95%CI 1.813?21.058) were adverse prognostic factors of PFS in patients with thyroid DLBCL. Ann Arbor Ⅲ?Ⅳ (HR=7.088, 95%CI 0.827?60.717), elevated LDH (HR=6.982, 95%CI 0.809?60.266), and DE (HR=18.079, 95%CI 1.837?177.923) were adverse prognostic factors of overall survival (OS). Multivariate analysis showed that Ann Arbor Ⅲ?Ⅳ (HR=4.693, 95%CI 1.218?18.081) and elevated LDH (HR=5.058, 95%CI 1.166?21.941) were independent adverse prognostic factors of PFS in patients with thyroid DLBCL. Targeted sequencing data showed mutation frequency >20% in TET2 (n=14, 35%), KMT2D (n=13, 32%), TP53 (n=11, 28%), GNA13 (n=10, 25%), KMT2C (n=9, 22%), and TP53 were adverse prognostic factors of PFS in patients with thyroid DLBCL (P=0.000). Conclusion ·Patients with primary thyroid DLBCL have better PFS and OS than those with secondary thyroid DLBCL. Ann Arbor Ⅲ?Ⅳ, elevated LDH, non-GCB, and DE (MYC and BCL2) are adverse prognostic factors in thyroid DLBCL. TET2,KMT2D, TP53, GNA13, and KMT2C are commonly highly mutated genes in thyroid DLBCL, and the prognosis of patients with TP53 mutations is poor.

Key words： thyroid; diffuse large B-cell lymphoma (DLBCL); clinicopathologic characteristic; gene mutation profile; prognostic analysis

参考文献

1 YI J, YI P, WANG W, et al. A multicenter retrospective study of 58 patients with primary thyroid diffuse large B cell lymphoma[J]. Front Endocrinol (Lausanne), 2020, 11: 542.
2 TRAVAGLINO A, PACE M, VARRICCHIO S, et al. Hashimoto thyroiditis in primary thyroid non-Hodgkin lymphoma[J]. Am J Clin Pathol, 2020, 153(2): 156-164.
3 WALSH S, LOWERY A J, EVOY D, et al. Thyroid lymphoma: recent advances in diagnosis and optimal management strategies[J]. Oncologist, 2013, 18(9): 994-1003.
4 PAVLIDIS E T, PAVLIDIS T E. A review of primary thyroid lymphoma: molecular factors, diagnosis and management[J]. J Invest Surg, 2019, 32(2): 137-142.
5 GRAFF-BAKER A, ROMAN S A, THOMAS D C, et al. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1, 408 cases[J]. Surgery, 2009, 146(6): 1105-1115.
6 KIM H C, HAN M H, KIM K H, et al. Primary thyroid lymphoma: CT findings[J]. Eur J Radiol, 2003, 46(3): 233-239.
7 KESIREDDY M, LASRADO S. Thyroid Lymphoma[M/OL]. Treasure Island (FL): StatPearls Publishing, 2023[2023-06-01]. https://www.ncbi.nlm.nih.gov/books/NBK544282/.
8 SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
9 CHESON B D, FISHER R I, BARRINGTON S F, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068.
10 中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735.
10 China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare. Clinical practice guideline for lympoma in China (2021 Edition)[J]. Chinese Journal of Oncology, 2021, 43(7): 707-735.
11 ZHU Y, YANG S, HE X. Prognostic evaluation models for primary thyroid lymphoma, based on the SEER database and an external validation cohort[J]. J Endocrinol Invest, 2022, 45(4): 815-824.
12 KNIEF J, GEBAUER N, BERNARD V, et al. Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid: a study of 21 cases[J]. J Clin Endocrinol Metab, 2015, 100(2): 754-762.
13 孙芮, 施晴, 沈容, 等. 原发与继发甲状腺淋巴瘤的临床特征和预后比较[J]. 中华血液学杂志, 2019, 40(7): 568-572.
13 SUN R, SHI Q, SHEN R, et al. Comparisons of clinical characteristics and prognosis between patients with primary and secondary thyroid lymphoma[J]. Chinese Journal of Hematology, 2019, 40(7): 568-572.
14 WRIGHT G W, HUANG D W, PHELAN J D, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J]. Cancer Cell, 2020, 37(4): 551-568.e14.
15 SHUKLA V, SAMANIEGO-CASTRUITA D, DONG Z, et al. TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures[J]. Nat Immunol, 2022, 23(1): 99-108.
16 SHOUVAL R, TOMAS A A, FEIN J A, et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy[J]. J Clin Oncol, 2022, 40(4): 369-381.
17 SHEN R, FU D, DONG L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma[J]. Signal Transduct Target Ther, 2023, 8(1): 145.
Options
文章导航

/

〈 〉